Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com 4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 4 years ago
3 Changes We Should Make to Address the Gender Pay Gap in Medicine
@xconomy.com 4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com 4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com 5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com 5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com 5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com 5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com 5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com 5 years ago
Digital Tools, Online Community & More: Patient Partnership Award Finalists
@xconomy.com 5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M